Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising demand for vaccines
3.2.1.2 Increasing adoption of outsourcing services
3.2.1.3 Technological advancements in vaccine technologies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.2.2.2 Increasing cost of vaccines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Attenuated
5.3 Inactivated
5.4 Subunit-based
5.5 Toxoid-based
5.6 DNA-based
Chapter 6 Market Estimates and Forecast, By Scale of Operation, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Commercial
6.3 Clinical
6.4 Preclinical
Chapter 7 Market Estimates and Forecast, By Service, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Fill-finish
7.3 Bulk vaccines
Chapter 8 Market Estimates and Forecast, By Product Type, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Combination vaccine
8.3 Single vaccine
Chapter 9 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Human
9.3 Veterinary
Chapter 10 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 Pharmaceutical & biotechnology companies
10.3 Academic and research institutes
Chapter 11 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Netherlands
11.3.7 Rest of Europe
11.4 Asia Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest of Latin America
11.6 Middle East and Africa
11.6.1 South Africa
11.6.2 Saudi Arabia
11.6.3 UAE
11.6.4 Rest of Middle East and Africa
Chapter 12 Company Profiles
12.1 Ajinomoto Co., Inc.
12.2 Bavarian Nordic A/S
12.3 Catalent, Inc
12.4 Charles River Laboratories International Inc.
12.5 Curia Global, Inc.
12.6 Cytovance Biologics (Hepalink)
12.7 Emergent BioSolutions Inc.
12.8 Fujifilm Holdings Corporation
12.9 Goodwin Biotechnology Inc.
12.10 Gedeon Richter (Richter-Helm BioLogics)
12.11 ICON PLC
12.12 IDT Biologika GmbH
12.13 Lonza Group AG
12.14 Recipharm AB
12.15 Syngene International Limited
